Acceleron’s TGF-beta Ligand Trap, Trillium’s SIRP-alpha Fusion Proteins, and Eight Other Large Molecules Acquired in 2021

Our team conducted a review of all of the biotech mergers and acquisitions of 2021 and distilled it down to the acquisitions of drug discovery-focused biotechs here. There were 10 acquisitions of companies with large molecule drug assets in 2021. Here is a more in-depth look into all of the lead large molecules acquired in 2021, including a review of: 

• The financial details of the acquisition/merger
• The mechanism of action and indication of each lead molecule
• The stage of clinical development for each lead molecule

Drug Discovery Biotech M&As: Large Molecules Deep Dive (Part 6)

Navigate the 2021 M&A Series

• the top overall drug discovery M&A transactions by value (Part 1)
• the transactions with disclosed upfront payments (Part 2)
• the most valuable small molecule acquisitions (Part 3)
• the most valuable large molecule transactions (Part 4)
• the small molecules acquired in 2021 M&A: deep dive (Part 5)